上海谊众药业股份有限公司 关于出售已回购股份的进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688091 证券简称：上海谊众 公告编号：2026-003 截至 2026 年 1 月 31 日，公司尚未出售已回购股份。 一、出售主体出售前基本情况 1 股东名称 上海谊众药业股份有限公司回购专用证券账户 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 □是 √否 董事、监事和高级管理人员 □是 √否 其他：回购专用证券账户 持股数量 1,904,896股 持股比例 0.92% 当前持股股份来源 集中竞价交易取得：1,904,896股 上述减持主体无一致行动人。 二、出售计划的实施进展 （一）股东因以下原因披露出售计划实施进展： 回购股份的基本情况 为维护公司价值与股东权益，上海谊众药业股份有限公司（以下简称"公 司"）于 2024 年 8 月 26 日——2024 年 12 月 25 日累计回购公司股份 1,274,307 股（详情请参阅公司于 20 ...

Core Viewpoint - The shareholders of Shanghai Yizhong Pharmaceutical Co., Ltd. plan to reduce their holdings, which may impact the company's stock performance but is not expected to significantly affect its governance structure or ongoing operations [12]. Shareholder Holding Situation - As of the announcement date, shareholder Li Feng holds 7,001,280 shares, accounting for 3.39% of the total share capital; Li Xun holds 6,740,986 shares, or 3.26%; and Xu Yuexiang holds 1,544,335 shares, or 0.75%. These shareholders are considered acting in concert with the company's director and deputy general manager, Li Duan [2]. Details of the Reduction Plan - Li Feng intends to reduce his holdings by up to 511,350 shares through centralized bidding (0.247% of total share capital) and up to 2,067,000 shares through block trading (0.999%). Li Xun has the same reduction intentions as Li Feng [3]. - Xu Yuexiang plans to reduce her holdings by up to 1,044,335 shares through centralized bidding (0.505% of total share capital). The total reduction across the three shareholders is up to 6,201,035 shares, or 2.997% of the total share capital [4]. Reduction Timing and Conditions - The reduction through centralized bidding will occur within three months after 15 trading days from the announcement date, with a limit of 1% of total shares in any consecutive 90-day period. The block trading reduction will start three trading days after the announcement and is limited to 2% of total shares in any consecutive 90-day period [4]. Shareholder Commitments - The shareholders have made commitments regarding their holdings, including a lock-up period of twelve months post-listing, during which they will not transfer or manage their shares. This commitment extends to three full accounting years if the company has not achieved profitability [8][9].

Core Viewpoint - Shanghai Yizhong (688091.SH) announced that major shareholders plan to reduce their holdings through both centralized bidding and block trading methods, potentially impacting the stock's market performance [1] Group 1: Shareholder Reduction Plans - Li Feng intends to reduce his holdings by up to 511,350 shares through centralized bidding, representing 0.247% of the total share capital, and by up to 2,067,000 shares through block trading, representing 0.999% of the total share capital [1] - Li Xun also plans to reduce his holdings by up to 511,350 shares through centralized bidding and by up to 2,067,000 shares through block trading, with the same percentage impacts as Li Feng [1] - Xu Yuexiang plans to reduce his holdings by up to 1,044,335 shares through centralized bidding, representing 0.505% of the total share capital [1] Group 2: Total Reduction Overview - The total number of shares that the three shareholders plan to reduce is up to 6,201,035 shares, which accounts for 2.997% of the company's total share capital [1] - The reduction period for shares through centralized bidding will occur within three months after the announcement, starting 15 trading days post-announcement, with a limit of 1% of total shares in any consecutive 90-day period [1] - For block trading, the reduction will also take place within three months after the announcement, starting three trading days post-announcement, with a limit of 2% of total shares in any consecutive 90-day period [1]

上海谊众药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688091 证券简称：上海谊众 公告编号：2026-002 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海谊众药业股份有限公司（以下简称"公司"）股东 李峰持有公司股份 7,001,280 股，占公司总股本的 3.39%；李循持有公司股份 6,740,986 股，占公司总股本的 3.26%；许越香持有公司股份 1,544,335 股，占 公司总股本的 0.75%。李峰、李循、许越香与公司董事、副总经理李端先生构成 一致行动人关系。上述股东持股来源为公司首次公开发行前取得的股份以及公司 历次实施资本公积转增股本取得的股份，且已于 2022 年 9 月 9 日解除限售并上 市流通。 李峰拟通过集中竞价方式减持所持有的股份不超过 511,350 股，不超过公司 总股本的 0.247%；拟通过大宗交易方式减持所持有的股份不超过 2,067,000 股， 不超过公司总股本的 0.999%。 李循拟通过集 ...

证券代码：688091 证券简称：上海谊众 公告编号：2026-002 上海谊众药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 李峰拟通过集中竞价方式减持所持有的股份不超过 511,350 股，不超过公司 总股本的 0.247%；拟通过大宗交易方式减持所持有的股份不超过 2,067,000 股， 不超过公司总股本的 0.999%。 李循拟通过集中竞价方式减持所持有的股份不超过 511,350 股，不超过公司 总股本的 0.247%；拟通过大宗交易方式减持所持有的股份不超过 2,067,000 股， 不超过公司总股本的 0.999%。 许越香拟通过集中竞价方式减持所持有的股份不超过 1,044,335 股，不超过 公司总股本的 0.505%。 上述三人拟减持所持有的公司股份合计不超过 6,201,035 股，不超过公司总 1 股本的 2.997%（窗口期等不得减持期间不减持）。本次减持期间，通过集中竞价 方式减持的，自本公告披露之日起 15 个交易日后的 3 个月内进行，且 ...

格隆汇1月30日｜上海谊众公告，截至披露日，李峰持股700.13万股，李循674.1万股，许越香154.43万 股。三人拟合计减持不超620.1万股，占2.997%。李峰拟集中竞价51.13万股、大宗交易206.7万股；李循 集中竞价51.13万股、大宗交易206.7万股；许越香集中竞价104.43万股。集中竞价减持期2026年3月3日 ～2026年6月2日，大宗交易期2026年2月5日～2026年4月30日。 ...

Group 1 - Shanghai Yizhong's stock price decreased by 1.55% on January 29, with a trading volume of 191 million yuan [1] - The financing data for January 29 shows a financing purchase amount of 13.20 million yuan and a financing repayment of 13.47 million yuan, resulting in a net financing outflow of 272,500 yuan [1] - As of January 29, the total balance of margin trading for Shanghai Yizhong is 597 million yuan, with a financing balance of 595 million yuan, accounting for 5.35% of the circulating market value, which is above the 80th percentile level over the past year [1] Group 2 - As of September 30, the number of shareholders for Shanghai Yizhong increased by 23.49% to 8,053, while the average circulating shares per person decreased by 19.02% to 25,667 shares [2] - For the period from January to September 2025, Shanghai Yizhong reported a revenue of 243 million yuan, representing a year-on-year growth of 43.35%, and a net profit attributable to shareholders of 50.66 million yuan, up 46.12% year-on-year [2] - Since its A-share listing, Shanghai Yizhong has distributed a total of 92.23 million yuan in dividends over the past three years [2]

Core Insights - The article highlights the early disclosure of annual performance forecasts by over 260 companies on the STAR Market, with approximately 40% of them reporting positive growth or recovery in profits [1] - The focus is on the connection between the STAR Market and national technology innovation strategies, particularly in sectors like artificial intelligence and biomedicine, attracting quality companies and long-term capital [1] Group 1: Performance Forecasts - As of January 29, over 260 STAR Market companies have disclosed their 2025 performance forecasts, with 62 companies expecting profit increases, 34 companies turning losses into profits, and 51 companies reducing losses [1] - Among the companies forecasting profit increases, over 30 are expected to see net profit growth exceeding 100%, while 26 companies anticipate growth between 50% and 100% [2] Group 2: Industry Trends - The companies expecting profit growth are primarily in hardware, semiconductors, and biomedicine sectors, benefiting from recovering industry demand and breakthroughs in products [2] - Shanghai Yizhong expects the highest net profit increase of 760.18%, driven by its core product being included in the national medical insurance directory, significantly boosting market access and patient numbers [2] Group 3: Order Growth - Order growth is identified as a key driver for performance increases among some STAR Market companies, with significant new orders contributing to revenue growth [2] - Chip Origin Co. anticipates a narrowing of net losses, supported by record-high new orders, with total new orders for 2025 reaching 5.96 billion, a year-on-year increase of 103.41% [4] - Companies like Aifute have also reported substantial new orders, indicating positive future impacts on their performance [4]

Core Viewpoint - The 2025 performance forecasts for companies listed on the Sci-Tech Innovation Board show promising results, with nearly 250 companies disclosing their earnings, and around 50% of them expected to be profitable, indicating a recovery in market demand and growth in emerging industries such as semiconductors, biomedicine, and artificial intelligence [1] Group 1: Company Performance - 125 companies are expected to achieve profitability, with 67 companies forecasting positive growth in net profit year-on-year, and 29 companies anticipating a profit increase of over 100% [1][2] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, followed by Zhenlei Technology and Baiwei Storage with expected increases of 529.64% to 642.26% and 427.19% to 520.22%, respectively [2] - Baiao Saitu anticipates a significant net profit increase of 384.26% to 443.88%, driven by its advanced antibody platform and collaborations with major companies [4] Group 2: Industry Trends - The semiconductor, biomedicine, and AI sectors are experiencing a surge in demand, contributing to the overall positive performance of the Sci-Tech Innovation Board companies [1][3] - Companies like Shijia Photon are benefiting from the AI boom, with a projected net profit increase of 425.95% due to rising orders in the data communication market [5] - The PCB and CCL industries are also seeing growth, with companies like Shengyi Electronics and Nanya New Materials expecting substantial profit increases due to high-quality orders and market expansion [6][7] Group 3: International Expansion - Many companies are actively pursuing international markets, with Pioneering Technology expecting a net profit of 62 million to 86 million yuan, a year-on-year increase of 50.82% to 109.21%, driven by international demand for energy storage solutions [3] - The internationalization strategy is becoming a key path for high-quality development among listed companies [3]

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]